MarketCap
Facebook
X
Telegram
Genetron Holdings Limited Revenue | GTH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Genetron Holdings Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 651 M | 532 M | 424 M | 323 M | 225 M | 101 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 651 M | 101 M | 376 M |
Quarterly Revenue Genetron Holdings Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 651 M | - | - | - | 532 M | - | - | - | 424 M | - | - | - | 323 M | - | - | - | 225 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 651 M | 225 M | 431 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
NeoGenomics
NEO
|
727 M | $ 15.29 | -3.72 % | $ 1.96 B | USA |
 |
Neogen Corporation
NEOG
|
870 M | $ 12.04 | 4.42 % | $ 2.62 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Natera
NTRA
|
2.31 B | $ 267.76 | -0.7 % | $ 36.6 B | USA |
 |
OPKO Health
OPK
|
148 M | $ 1.32 | -1.12 % | $ 991 M | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 416.3 | 2.6 % | $ 29.2 B |  Schweiz |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 26.3 | -0.53 % | $ 24.9 B |  Niderland |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Personalis
PSNL
|
69.6 M | $ 12.66 | 3.09 % | $ 1.13 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Quidel Corporation
QDEL
|
1.66 B | $ 16.77 | 1.21 % | $ 706 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 1.98 | 0.51 % | $ 131 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
7.66 M | - | - | $ 7.1 B |  Australia |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 43.71 | 14.72 % | $ 2.33 B | USA |
 |
Waters Corporation
WAT
|
932 M | $ 377.31 | -0.79 % | $ 22.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
8.25 B | $ 163.57 | -1.19 % | $ 12.8 B |  Irlanda |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
190 M | - | - | $ 2.69 B | USA |
 |
Exagen
XGN
|
66.6 M | $ 4.53 | -3.0 % | $ 97.7 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 233.01 | -0.58 % | $ 25.9 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Biomerica
BMRA
|
5.31 M | $ 1.49 | -6.28 % | $ 3.42 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
131 K | - | -2.3 % | $ 19.4 M | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 7.27 | -1.76 % | $ 29 M | Israel |
 |
OpGen
OPGN
|
30.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 3.42 | -3.93 % | $ 111 K | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.44 | -7.69 % | $ 1.92 M | USA |
 |
DexCom
DXCM
|
4.66 B | $ 83.45 | 11.95 % | $ 32.6 B | USA |
 |
Psychemedics Corporation
PMD
|
19.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
38.5 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
7.19 M | - | -39.35 % | $ 313 K | USA |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | USA |